Rhythm Pharmaceuticals, Inc. (RYTM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 06, 2025

$58.97

P/E Ratio

N/A

Market Cap

$3.62B

Jan 18, 2024Feb 22, 2024Mar 27, 2024May 1, 2024Jun 4, 2024Jul 8, 2024Aug 7, 2024Sep 11, 2024Oct 16, 2024Nov 20, 2024Jan 6, 2025$50.00$60.00$70.00$80.00
  • GEF
Description

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Metrics

Overview

  • HQBoston, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerRYTM
  • Price$58.97-1.09%

Trading Information

  • Market cap$3.62B
  • Float87.33%
  • Average Daily Volume (1m)541,534
  • Average Daily Volume (3m)543,176
  • EPS-$4.34

Company

  • Revenue$112.53M
  • Rev growth (1yr)47.76%
  • Net income-$43.64M
  • Gross margin87.97%
  • EBITDA margin-130.82%
  • EBITDA-$43.50M
  • EV$3.16B
  • EV/Revenue28.11
  • P/EN/A
  • P/S32.08
  • P/B323.04
Documents